NSAIDs and gastrointestinal complications: New clinical challenges

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 15, 2005, Pages 2681-2689

  Abraham, Neena S ^a   Graham, David Y ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

COX 2 inhibitor; Coxib; NSAIDs; Peptic ulcer; Upper gastrointestinal tract bleeding

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; ETODOLAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; KETOROLAC; LANSOPRAZOLE; MELOXICAM; MISOPROSTOL; NABUMETONE; NAPROXEN; NIMESULIDE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PIROXICAM; PLACEBO; RANITIDINE; ROFECOXIB; SULINDAC; VALDECOXIB; WARFARIN;

AGING; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CORRELATION ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DYSPEPSIA; ELDERLY CARE; ENTERIC COATED TABLET; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HELICOBACTER INFECTION; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; META ANALYSIS; MORBIDITY; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; STROKE; TOOTH PAIN;

AGE FACTORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; GASTROINTESTINAL DISEASES; HUMANS; RISK FACTORS;

EID: 29244474359     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.15.2681     Document Type: Review

References (74)

1. SINGH G, ROSEN RD: NSAID induced gastrointestinal complications: the ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System. J. Rheumatol. (1998) 51(Suppl.):8-16.
2. THOMAS J, STRAUS WL, BLOOM BS: Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms. Am. J. Gastroenterol. (2002) 97(9):2215-2219.
3. SCHEIMAN JM, FENDRICK AM: NSAIDs without a prescription: over-the-counter access, under-counted risks. Am. J. Gastroenterol. (2002) 97(9):2159-2161.
4. GOLDSTEIN JL, LEFKOWITH J: Public misunderstanding of non-steroidal anti-inflammatory drug (NSAID)-mediated gastrointestinal (GI) toxicity: a serious potential health threat. Gastroenterology (1998) 114:A555 (Abstr.).
5. GABRIEL SE, JAAKKIMAINEN L, BOMBARDIER C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann. Intern. Med. (1991) 115(10):787-796.
6. MCCARTHY D: Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. Am. J. Med. (1998) 105(5A):3S-9S.
7. SMALLEY WE, RAY WA, DAUGHERTY JR, GRIFFIN MR: Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am. J. Epidemiol. (1995) 141(6):539-545.
8. BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. (2000) 343(21):1520-1528.
9. OFMAN JJ, MACLEAN CH, STRAUS WL et al.: A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J. Rheumatol. (2002) 29(4):804-812.
10. WOLFE MM, LICHTENSTEIN DR, SINGH G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. (1999) 340(24):1888-1899.
11. SMALLEY WE, GRIFFIN MR, FOUGHT RL, RAY WA: Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J. Gen. Intern. Med. (1996) 11(8):461-469.
12. LAINE L, WOGEN J, YU H: Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs. Gastroenterology (2003) 125(2):389-395.
13. RAHME E, JOSEPH L, KONG SX, WATSON DJ, LELORIER J: Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum. (2000) 43(4):917-924.
14. SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA (2000) 284(10):1247-1255.
15. HERNANDEZ-DIAZ S, GARCIA-RODRIGUEZ LA: Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am. J. Med. (2001) 110(Suppl. 3A):20S-27S.
16. TARONE RE, BLOT WJ, MCLAUGHLIN JK: Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am. J. Ther. (2004) 11(1):17-25.
17. GARCIA RODRIGUEZ LA, JICK H: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 343(8900):769-772.
18. HENRY D, LIM LL, GARCIA RODRIGUEZ LA et al.: Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ (1996) 312(7046):1563-1566.
19. FRIES JF, WILLIAMS CA, BLOCH DA: The relative toxicity of nonsteroidal antiinflammatory drugs. Arthritis. Rheum. (1991) 34(11):1353-1360.
20. WEIDEMAN RA, KELLY KC, KAZI S et al.: Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis. Gastroenterology (2004) 127(5):1322-1328.
21. HUANG JQ, SRIDHAR S, HUNT RH: Gastrointestinal safety profile of nabumetone: a meta-analysis. Am. J. Med. (1999) 107(6A):55S-61S.
22. SCHOENFELD P: Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am. J. Med. (1999) 107(6A):48S-54S.
23. HUNT RH, BARKUN AN, BARON D et al.: Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents. Can. J. Gastroenterol. (2002) 16(4):231-240.
24. WARNER TD, GIULIANO F, VOJNOVIC I, BUKASA A, MITCHELL JA, VANE JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. USA (1999) 96(13):7563-7568.
25. CHAN FK, GRAHAM DY: Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications-review and recommendations based on risk assessment. Aliment. Pharmacol. Ther. (2004) 19(10):1051-1061.
26. COOPER SA, WAGENBERG B, ESKOW R, ZISSU J: Double-blind evaluation of ibuprofen and aspirin in the treatment of periodontal pain. Pharmacology (1983) 27(Suppl. 1):23-30.
27. LANAS A, SEKAR MC, HIRSCHOWITZ BI: Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology (1992) 103(3):862-869.
28. MAJERUS PW, STANFORD N: Comparative effects of aspirin and diflunisal on prostaglandin synthetase from human platelets and sheep seminal vesicles. Br. J. Clin. Pharmacol. (1977) 4(Suppl. 1):15S-18S.
29. GRAHAM DY: Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am. J. Gastroenterol. (1996) 91(10):2080-2086.
30. JONES RA: Etodolac: clinical profile of an established selective cyclooxygenase-2 inhibitor. In: Therapeutic Roles of Selective COX-2 Inhibitors. Vane JR, Botting RM (Eds). William Harvey Press, London (2001):482-497.
31. SILVERSTEIN FE, GRAHAM DY, SENIOR JR RM et al.: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1995) 123(4):241-249.
32. GRAHAM DY, WHITE RH, MORELAND LW et al.: Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann. Intern. Med. (1993) 119(4):257-262.
33. CHAN FK, CHUNG SC, SUEN BY et al.: Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med. (2001) 344(13):967-973.
34. GRAHAM DY, AGRAWAL NM, CAMPBELL DR et al.: Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol versus lansoprazole. Arch. Intern. Med. (2002) 162(2):169-175.
35. YEOMANS ND, TULASSAY Z, JUHASZ L et al.: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N. Engl. J. Med. (1998) 338(11):719-726.
36. GRAHAM DY: Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users. Helicobacter (2002) 7(1):1-8.
37. GRAHAM DY: NSAIDs, Helicobacter pylori, and Pandora's Box. N. Engl. J. Med. (2002) 347(26):2162-2164.
38. LANZA FL: A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am. J. Gastroenterol. (1998) 93(11):2037-2046.
39. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. (2000) 43(9):1905-1915.
40. SCHNITZER TJ: Update of ACR guidelines for osteoarthritis: role of the coxibs. J. Pain Symptom Manage. (2002) 23(4 Suppl.):S24-S30.
41. AGRAWAL NM, CALDWELL J, KIVITZ AJ et al.: Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal antiinflammatory drug-induced gastrointestinal ulcers. Clin. Ther. (1999) 21(4):659-674.
42. BOCANEGRA TS, WEAVER AL, TINDALL EA et al.: Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group. J. Rheumatol. (1998) 25(8):1602-1611.
43. LISSE JR, PERLMAN M, JOHANSSON G et al.: Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann. Intern. Med. (2003) 139(7):539-546.
44. PEURA DA, LANZA FL, GOSTOUT CJ, FOUTCH PG: The American College of Gastroenterology Bleeding Registry: preliminary findings. Am. J. Gastroenterol. (1997) 92(6):924-928.
45. COX ER, FRISSE M, BEHM A, FAIRMAN KA: Over-the-counter pain reliever and aspirin use with a sample of long-term cyclooxygenase 2 users. Arch. Intern. Med. (2004) 164:1243-1245.
46. LEWIS JD, BILKER WB, BRENSINGER C, FARRAR JT, STROM BL: Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am. J. Gastroenterol. (2002) 97(10):2540-2549.
47. SCHEIMAN JM, CRYER B, KIMMEY MB, ROTHSTEIN RI, RIFF DS, WOLFE MM: A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury. Clin. Gastroenterol. Hepatol. (2004) 2(4):290-295.
48. HUANG JQ, SRIDHAR S, HUNT RH: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet (2002) 359(9300):14-22.
49. MALFERTHEINER P, MEGRAUD F, O'MORAIN C et al.: Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment. Pharmacol. Ther. (2002) 16(2):167-180.
50. GRAHAM DY, LEW GM, KLEIN PD et al.: Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann. Intern. Med. (1992) 116(9):705-708.
51. CHAN FK, SUNG JJ, CHUNG SC et al.: Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet (1997) 350(9083):975-979.
52. GRAHAM DY, HEPPS KS, RAMIREZ FC, LEW GM, SAFED ZA: Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand. J. Gastroenterol. (1993) 28(11):939-942.
53. DERRY S, LOKE YK: Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ (2000) 321(7270):1183-1187.
54. WEIL J, COLIN-JONES D, LANGMAN M et al.: Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ (1995) 310(6983):827-830.
55. SORENSEN HT, MELLEMKJAER L, BLOT WJ et al.: Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am. J. Gastroenterol. (2000) 95(9):2218-2224.
56. WILCOX CM, SHALEK KA, COTSONIS G: Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage. Arch. Intern. Med. (1994) 154(1):42-46.
57. LAUER MS: Clinical practice. Aspirin for primary prevention of coronary events. N. Engl. J. Med. (2002) 346(19):1468-1474.
58. RAY WA, STEIN CM, HALL K, DAUGHERTY JR, GRIFFIN MR: Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet (2002) 359(9301):118-123.
59. GARCIA RODRIGUEZ LA, HERNANDEZ-DIAZ S: The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. (2001) 3(2):98-101.
60. LAINE L: Gastrointestinal effects of NSAIDs and coxibs. J. Pain Symptom Manage. (2003) 25(2 Suppl.):S32-S40.
61. KIMMEL SE, BERLIN JA, REILLY M et al.: The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J. Am. Coll. Cardiol. (2004) 43(6):985-990.
62. RAHME E, BARDOU M, DASGUPTA K, BARKUN A: Gastrointestinal effects of rofecoxib and celecoxib versus NSAIDs among patients on low dose aspirin. Gastroenterology (2004) 126(4 Suppl. 2):9 (Abstr.).
63. FITZGERALD GA, PATRONO C: The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. (2001) 345(6):433-442.
64. SINGH D: Merck withdraws arthritis drug worldwide, BMJ (2004) 329(7470):816.
65. OTT E, NUSSMEIER NA, DUKE PC et al.: Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. (2003) 125(6):1481-1492.
66. SOLOMON SD, MCMURRAY JJV, PFEFFER MA et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. (2005) 352(11):1071-1080.
67. KIMMEL SE, BERLIN JA, REILLY M et al.: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann. Intern. Med. (2005) 142(3):157-164.
68. TALLEY NJ, EVANS JM, FLEMING KC, HARMSEN WS, ZINSMEISTER AR, MELTON LJ III: Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig. Dis. Sci. (1995) 40(6):1345-1350.
69. GARCIA RODRIGUEZ LA, HERNANDEZ-DIAZ S: Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am. J. Epidemiol. (2004) 159(1):23-31.
70. HANSEN JM, HALLAS J, LAURITSEN JM, BYTZER P: Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand. J. Gastroenterol. (1996) 31(2):126-130.
71. GRIFFIN MR, RAY WA, SCHAFFNER W: Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann. Intern. Med. (1988) 109(5):359-363.
72. GRIFFIN MR, PIPER JM, DAUGHERTY JR, SNOWDEN M, RAY WA: Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann. Intern. Med. (1991) 114(4):257-263.
73. LAINE L, BOMBARDIER C, HAWKEY CJ et al.: Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology (2002) 123(4):1006-1012.
74. SHORR RI, RAY WA, DAUGHERTY JR, GRIFFIN MR: Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch. Intern. Med. (1993) 153(14):1665-1670.